Aurora Oncology, founded in Aurora, Colorado, is a pioneering software company focused on advancing cancer diagnostics and treatments. The company's mission is to translate groundbreaking research into practical solutions for patients with targetable tumors, particularly bladder cancer. Aurora Oncology's core product is an EGF-toxin fusion protein, a modified EGF-diphtheria toxin with enhanced affinity for the EGF receptor, which is often overexpressed on cancer cells. Their market focus is on developing innovative drugs and diagnostics to improve cancer care.

The company was established by researchers from the University of Colorado Cancer Center, who bring extensive expertise in oncology. Aurora Oncology has garnered attention for its cutting-edge approach to cancer treatment, leveraging scientific discoveries to create impactful medical solutions. The company's notable achievements include the development of their lead molecule, which promises to offer more effective treatment options for bladder cancer patients. Aurora Oncology continues to make significant strides in the field of oncology, aiming to improve patient outcomes through advanced therapeutic and diagnostic technologies.